Krsnaa Diagnostics Approves FY26 Audited Results & Recommends 40% Final Dividend
Krsnaa Diagnostics Limited reported audited standalone and consolidated results for FY26. The company recommended a final dividend of ₹2 per share (40%). The Board approved the appointment of M/s Kirtane & Pandit LLP as Statutory Auditors for FY27-FY31.
The approval of financial results and dividend recommendation are important corporate actions. The appointment of auditors is a routine but necessary process. The financial performance, while positive, does not indicate an extraordinary event, hence the medium impact.
The company reported its audited financial results and recommended a final dividend, which are generally positive developments for shareholders. The unmodified audit opinion further strengthens the positive sentiment.
Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on May 25, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The Statutory Auditors have issued an unmodified opinion on these results.
Additionally, the Board recommended a final dividend of ₹2 per equity share (40% of face value) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
The Board also approved several auditor appointments and re-appointments for the financial year 2026-27, including M/s Kirtane & Pandit LLP as Statutory Auditors, M/s Mahajan & Aibara Chartered Accountants LLP as Internal Auditors, Harshad S. Deshpande & Associates as Cost Auditors, and M/s V. A. Dudhedia and Co. as Tax Auditors.
The financial results indicate a Profit Before Tax of ₹1,323.21 million for the standalone entity and ₹1,303.67 million for the consolidated entity for the year ended March 31, 2026. Revenue from operations for the year stood at ₹6,909.47 million (standalone) and ₹7,727.74 million (consolidated). The company reported a Profit After Tax of ₹1,026.75 million (standalone) and ₹1,014.31 million (consolidated) for the year.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.